Emergence of tigecycline resistance in <em>Escherichia coli</em> co-producing MCR-1 and NDM-5 during tigecycline salvage treatment

Abstract

This is the first report of a colistin-, carbapenem-, and tigecycline-resistant <i>E. coli</i> in China. Tigecycline resistance acquired during tigecycline therapy is of great concern for us because tigecycline is a drug of last resort to treat carbapenem-resistant Gram-negative bacterial infections. Furthermore, the transmission of such extensively drug-resistant isolates may pose a great threat to public health.